Since these genes are deregulated in a Shh-type MB whose frequency is enhanced by Tis21 ablation, and since Tis21 has been shown to be down-regulated in human MBs (mainly Shh-type), it is plausible a benefit using Cxcl3 in MB therapy of at least the Shh-type. This evidence concerns the gene BTG2 and Mobius syndrome.